Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction
Objective To assess the feasibility safety and side effects of the addition of atropine to dobutamine stress echocardio-graphy for the detection of viable myocardium in patients with left ventricular dysfunction (ejection fraction ≤35%) prior to coronary revascularization. Background The assessment...
Gespeichert in:
| Veröffentlicht in: | European heart journal 1998-11, Vol.19 (11), p.1712-1718 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1718 |
|---|---|
| container_issue | 11 |
| container_start_page | 1712 |
| container_title | European heart journal |
| container_volume | 19 |
| creator | Poldermans, D. Rambaldi, R. Bax, J.J. Cornel, J.H. Thomson, I.R. Valkema, R. Boersma, E. Fioretti, P.M. Breburda, C.S.M. Roelandt, J.R.T.C. |
| description | Objective To assess the feasibility safety and side effects of the addition of atropine to dobutamine stress echocardio-graphy for the detection of viable myocardium in patients with left ventricular dysfunction (ejection fraction ≤35%) prior to coronary revascularization. Background The assessment of viable and/or ischaemic myocardium has high prognostic value as regards improvement of function and survival after coronary revasculariz-ation. The addition of atropine to dobutamine during echocardiographic testing for the presence of viable myocardium is not common practice. Consequently, no data exist on the safety and additional diagnostic value of this practice. Methods Two hundred patients with left ventricular ejection fraction ≤35% were studied. Results Test end-points were: target heart rate in 164 (82%) of the patients, severe angina in 18 (9%), maximum dobutamine–atropine dose in six (3%), severe ST segment changes in five (2%), cardiac arrhythmias in four (2%), and hypotension in three (1%). Viability could be assessed echocardiogaphically in 105/200 (53%) from a biphasic response (improvement of wall motion with low dose dobutamine and worsening with high dose), in 93 from ischaemia and in 12 from sustained or late improvements. In 36/105 (34%) patients, ischaemic myocardium could only be assessed after the addition of atropine. Cardiac arrhythmias occurred in 11/200 (6%) and hypotension (decrease of systolic blood pressure >30mmHg) in 21/200 (11%). Neither the use of atropine nor the induction of ischaemia were associated with an increased incidence of cardiac arrhythmias or hypotension. Conclusions In a large group of patients with severe left ventricular dysfunction, dobutamine stress echocardiography is feasible and safe in 186/200 (93%); the addition of atropine was necessary in 34% to assess myocardial viability. Hypotension and cardiac arrhythmias were the most frequent side effects, but were not related to the induction of ischaemia or addition of atropine.The European Society of Cardiology |
| doi_str_mv | 10.1053/euhj.1998.1126 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1053_euhj_1998_1126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_HXZ_T93XWM5L_G</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-cd77185cd9af272b3f1e44ab9f8c5d3abc39cd71c00fea81606efb4fb5f8b1d23</originalsourceid><addsrcrecordid>eNpFkEtv1DAYRS0EKtPClh2SF2wz2PE4iZeooi3SVCwoYsTG-vxqXPKS7QzkT_EbcTSjsrLlc--VdRB6R8mWEs4-2rl92lIhmi2lZfUCbSgvy0JUO_4SbQgVvKiq5vAaXcb4RAhpKlpdoAvR8FqUfIP-fgNn04JhMHhOvvP5PjoMKYyTHywGY3zy44DNHPzwiM2o5gT9imIKNkZsdTtqCMaPjwGmdsFuDDi1uRpj5r0d0rp49KA6i_vlFJ577Ac8QfKZR_zbpxZHe7TB4s66hI_5OXg9dxCwWaKbB71-4w165aCL9u35vELfbz4_XN8V-6-3X64_7QvNeJ0KbeqaNlwbAa6sS8UctbsdKOEazQ0DpZnIGaoJcRYaWpHKOrVzirtGUVOyK7Q97eowxhisk1PwPYRFUiJX73L1LlfvcvWeC-9PhWlWvTXP8bPozD-cOUQNnQswaB__r3JRs7LJseIU8zHZP88Ywi9Z1azm8u7wUz4Idvhxz_fylv0Dc9mijA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Poldermans, D. ; Rambaldi, R. ; Bax, J.J. ; Cornel, J.H. ; Thomson, I.R. ; Valkema, R. ; Boersma, E. ; Fioretti, P.M. ; Breburda, C.S.M. ; Roelandt, J.R.T.C.</creator><creatorcontrib>Poldermans, D. ; Rambaldi, R. ; Bax, J.J. ; Cornel, J.H. ; Thomson, I.R. ; Valkema, R. ; Boersma, E. ; Fioretti, P.M. ; Breburda, C.S.M. ; Roelandt, J.R.T.C.</creatorcontrib><description>Objective To assess the feasibility safety and side effects of the addition of atropine to dobutamine stress echocardio-graphy for the detection of viable myocardium in patients with left ventricular dysfunction (ejection fraction ≤35%) prior to coronary revascularization. Background The assessment of viable and/or ischaemic myocardium has high prognostic value as regards improvement of function and survival after coronary revasculariz-ation. The addition of atropine to dobutamine during echocardiographic testing for the presence of viable myocardium is not common practice. Consequently, no data exist on the safety and additional diagnostic value of this practice. Methods Two hundred patients with left ventricular ejection fraction ≤35% were studied. Results Test end-points were: target heart rate in 164 (82%) of the patients, severe angina in 18 (9%), maximum dobutamine–atropine dose in six (3%), severe ST segment changes in five (2%), cardiac arrhythmias in four (2%), and hypotension in three (1%). Viability could be assessed echocardiogaphically in 105/200 (53%) from a biphasic response (improvement of wall motion with low dose dobutamine and worsening with high dose), in 93 from ischaemia and in 12 from sustained or late improvements. In 36/105 (34%) patients, ischaemic myocardium could only be assessed after the addition of atropine. Cardiac arrhythmias occurred in 11/200 (6%) and hypotension (decrease of systolic blood pressure >30mmHg) in 21/200 (11%). Neither the use of atropine nor the induction of ischaemia were associated with an increased incidence of cardiac arrhythmias or hypotension. Conclusions In a large group of patients with severe left ventricular dysfunction, dobutamine stress echocardiography is feasible and safe in 186/200 (93%); the addition of atropine was necessary in 34% to assess myocardial viability. Hypotension and cardiac arrhythmias were the most frequent side effects, but were not related to the induction of ischaemia or addition of atropine.The European Society of Cardiology</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1053/euhj.1998.1126</identifier><identifier>PMID: 9857925</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Atropine ; atropine addition ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiotonic Agents ; Dobutamine ; Dobutamine stress echocardiography ; Drug Synergism ; Electrocardiography ; Exercise Test - methods ; Feasibility Studies ; Female ; Heart ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heart Rate - drug effects ; Hemodynamics ; Humans ; Infusions, Intravenous ; Male ; Medical sciences ; Middle Aged ; Myocardial Ischemia - diagnostic imaging ; Myocardial Ischemia - physiopathology ; Parasympatholytics ; poor left ventricular function ; Ultrasonography ; Ventricular Dysfunction, Left - diagnostic imaging ; Ventricular Dysfunction, Left - physiopathology</subject><ispartof>European heart journal, 1998-11, Vol.19 (11), p.1712-1718</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-cd77185cd9af272b3f1e44ab9f8c5d3abc39cd71c00fea81606efb4fb5f8b1d23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1597328$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9857925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poldermans, D.</creatorcontrib><creatorcontrib>Rambaldi, R.</creatorcontrib><creatorcontrib>Bax, J.J.</creatorcontrib><creatorcontrib>Cornel, J.H.</creatorcontrib><creatorcontrib>Thomson, I.R.</creatorcontrib><creatorcontrib>Valkema, R.</creatorcontrib><creatorcontrib>Boersma, E.</creatorcontrib><creatorcontrib>Fioretti, P.M.</creatorcontrib><creatorcontrib>Breburda, C.S.M.</creatorcontrib><creatorcontrib>Roelandt, J.R.T.C.</creatorcontrib><title>Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Objective To assess the feasibility safety and side effects of the addition of atropine to dobutamine stress echocardio-graphy for the detection of viable myocardium in patients with left ventricular dysfunction (ejection fraction ≤35%) prior to coronary revascularization. Background The assessment of viable and/or ischaemic myocardium has high prognostic value as regards improvement of function and survival after coronary revasculariz-ation. The addition of atropine to dobutamine during echocardiographic testing for the presence of viable myocardium is not common practice. Consequently, no data exist on the safety and additional diagnostic value of this practice. Methods Two hundred patients with left ventricular ejection fraction ≤35% were studied. Results Test end-points were: target heart rate in 164 (82%) of the patients, severe angina in 18 (9%), maximum dobutamine–atropine dose in six (3%), severe ST segment changes in five (2%), cardiac arrhythmias in four (2%), and hypotension in three (1%). Viability could be assessed echocardiogaphically in 105/200 (53%) from a biphasic response (improvement of wall motion with low dose dobutamine and worsening with high dose), in 93 from ischaemia and in 12 from sustained or late improvements. In 36/105 (34%) patients, ischaemic myocardium could only be assessed after the addition of atropine. Cardiac arrhythmias occurred in 11/200 (6%) and hypotension (decrease of systolic blood pressure >30mmHg) in 21/200 (11%). Neither the use of atropine nor the induction of ischaemia were associated with an increased incidence of cardiac arrhythmias or hypotension. Conclusions In a large group of patients with severe left ventricular dysfunction, dobutamine stress echocardiography is feasible and safe in 186/200 (93%); the addition of atropine was necessary in 34% to assess myocardial viability. Hypotension and cardiac arrhythmias were the most frequent side effects, but were not related to the induction of ischaemia or addition of atropine.The European Society of Cardiology</description><subject>Adult</subject><subject>Aged</subject><subject>Atropine</subject><subject>atropine addition</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiotonic Agents</subject><subject>Dobutamine</subject><subject>Dobutamine stress echocardiography</subject><subject>Drug Synergism</subject><subject>Electrocardiography</subject><subject>Exercise Test - methods</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Heart</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Heart Rate - drug effects</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Ischemia - diagnostic imaging</subject><subject>Myocardial Ischemia - physiopathology</subject><subject>Parasympatholytics</subject><subject>poor left ventricular function</subject><subject>Ultrasonography</subject><subject>Ventricular Dysfunction, Left - diagnostic imaging</subject><subject>Ventricular Dysfunction, Left - physiopathology</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtv1DAYRS0EKtPClh2SF2wz2PE4iZeooi3SVCwoYsTG-vxqXPKS7QzkT_EbcTSjsrLlc--VdRB6R8mWEs4-2rl92lIhmi2lZfUCbSgvy0JUO_4SbQgVvKiq5vAaXcb4RAhpKlpdoAvR8FqUfIP-fgNn04JhMHhOvvP5PjoMKYyTHywGY3zy44DNHPzwiM2o5gT9imIKNkZsdTtqCMaPjwGmdsFuDDi1uRpj5r0d0rp49KA6i_vlFJ577Ac8QfKZR_zbpxZHe7TB4s66hI_5OXg9dxCwWaKbB71-4w165aCL9u35vELfbz4_XN8V-6-3X64_7QvNeJ0KbeqaNlwbAa6sS8UctbsdKOEazQ0DpZnIGaoJcRYaWpHKOrVzirtGUVOyK7Q97eowxhisk1PwPYRFUiJX73L1LlfvcvWeC-9PhWlWvTXP8bPozD-cOUQNnQswaB__r3JRs7LJseIU8zHZP88Ywi9Z1azm8u7wUz4Idvhxz_fylv0Dc9mijA</recordid><startdate>19981101</startdate><enddate>19981101</enddate><creator>Poldermans, D.</creator><creator>Rambaldi, R.</creator><creator>Bax, J.J.</creator><creator>Cornel, J.H.</creator><creator>Thomson, I.R.</creator><creator>Valkema, R.</creator><creator>Boersma, E.</creator><creator>Fioretti, P.M.</creator><creator>Breburda, C.S.M.</creator><creator>Roelandt, J.R.T.C.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19981101</creationdate><title>Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction</title><author>Poldermans, D. ; Rambaldi, R. ; Bax, J.J. ; Cornel, J.H. ; Thomson, I.R. ; Valkema, R. ; Boersma, E. ; Fioretti, P.M. ; Breburda, C.S.M. ; Roelandt, J.R.T.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-cd77185cd9af272b3f1e44ab9f8c5d3abc39cd71c00fea81606efb4fb5f8b1d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atropine</topic><topic>atropine addition</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiotonic Agents</topic><topic>Dobutamine</topic><topic>Dobutamine stress echocardiography</topic><topic>Drug Synergism</topic><topic>Electrocardiography</topic><topic>Exercise Test - methods</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Heart</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Heart Rate - drug effects</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Ischemia - diagnostic imaging</topic><topic>Myocardial Ischemia - physiopathology</topic><topic>Parasympatholytics</topic><topic>poor left ventricular function</topic><topic>Ultrasonography</topic><topic>Ventricular Dysfunction, Left - diagnostic imaging</topic><topic>Ventricular Dysfunction, Left - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poldermans, D.</creatorcontrib><creatorcontrib>Rambaldi, R.</creatorcontrib><creatorcontrib>Bax, J.J.</creatorcontrib><creatorcontrib>Cornel, J.H.</creatorcontrib><creatorcontrib>Thomson, I.R.</creatorcontrib><creatorcontrib>Valkema, R.</creatorcontrib><creatorcontrib>Boersma, E.</creatorcontrib><creatorcontrib>Fioretti, P.M.</creatorcontrib><creatorcontrib>Breburda, C.S.M.</creatorcontrib><creatorcontrib>Roelandt, J.R.T.C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poldermans, D.</au><au>Rambaldi, R.</au><au>Bax, J.J.</au><au>Cornel, J.H.</au><au>Thomson, I.R.</au><au>Valkema, R.</au><au>Boersma, E.</au><au>Fioretti, P.M.</au><au>Breburda, C.S.M.</au><au>Roelandt, J.R.T.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>1998-11-01</date><risdate>1998</risdate><volume>19</volume><issue>11</issue><spage>1712</spage><epage>1718</epage><pages>1712-1718</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Objective To assess the feasibility safety and side effects of the addition of atropine to dobutamine stress echocardio-graphy for the detection of viable myocardium in patients with left ventricular dysfunction (ejection fraction ≤35%) prior to coronary revascularization. Background The assessment of viable and/or ischaemic myocardium has high prognostic value as regards improvement of function and survival after coronary revasculariz-ation. The addition of atropine to dobutamine during echocardiographic testing for the presence of viable myocardium is not common practice. Consequently, no data exist on the safety and additional diagnostic value of this practice. Methods Two hundred patients with left ventricular ejection fraction ≤35% were studied. Results Test end-points were: target heart rate in 164 (82%) of the patients, severe angina in 18 (9%), maximum dobutamine–atropine dose in six (3%), severe ST segment changes in five (2%), cardiac arrhythmias in four (2%), and hypotension in three (1%). Viability could be assessed echocardiogaphically in 105/200 (53%) from a biphasic response (improvement of wall motion with low dose dobutamine and worsening with high dose), in 93 from ischaemia and in 12 from sustained or late improvements. In 36/105 (34%) patients, ischaemic myocardium could only be assessed after the addition of atropine. Cardiac arrhythmias occurred in 11/200 (6%) and hypotension (decrease of systolic blood pressure >30mmHg) in 21/200 (11%). Neither the use of atropine nor the induction of ischaemia were associated with an increased incidence of cardiac arrhythmias or hypotension. Conclusions In a large group of patients with severe left ventricular dysfunction, dobutamine stress echocardiography is feasible and safe in 186/200 (93%); the addition of atropine was necessary in 34% to assess myocardial viability. Hypotension and cardiac arrhythmias were the most frequent side effects, but were not related to the induction of ischaemia or addition of atropine.The European Society of Cardiology</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>9857925</pmid><doi>10.1053/euhj.1998.1126</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 1998-11, Vol.19 (11), p.1712-1718 |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1053_euhj_1998_1126 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Adult Aged Atropine atropine addition Biological and medical sciences Cardiology. Vascular system Cardiotonic Agents Dobutamine Dobutamine stress echocardiography Drug Synergism Electrocardiography Exercise Test - methods Feasibility Studies Female Heart Heart failure, cardiogenic pulmonary edema, cardiac enlargement Heart Rate - drug effects Hemodynamics Humans Infusions, Intravenous Male Medical sciences Middle Aged Myocardial Ischemia - diagnostic imaging Myocardial Ischemia - physiopathology Parasympatholytics poor left ventricular function Ultrasonography Ventricular Dysfunction, Left - diagnostic imaging Ventricular Dysfunction, Left - physiopathology |
| title | Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T07%3A59%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20utility%20of%20atropine%20addition%20during%20dobutamine%20stress%20echocardiography%20for%20the%20assessment%20of%20viable%20myocardium%20in%20patients%20with%20severe%20left%20ventricular%20dysfunction&rft.jtitle=European%20heart%20journal&rft.au=Poldermans,%20D.&rft.date=1998-11-01&rft.volume=19&rft.issue=11&rft.spage=1712&rft.epage=1718&rft.pages=1712-1718&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1053/euhj.1998.1126&rft_dat=%3Cistex_cross%3Eark_67375_HXZ_T93XWM5L_G%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9857925&rfr_iscdi=true |